ArticleFrontiers in pharmacology2025
Integrated metabolomic and transcriptomic analysis reveals the effects and mechanisms of Jingfang Baidu powder on acute lung injury.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lung injury (ALI) is one of the most prevalent respiratory diseases globally. Jingfang Baidu Powder (JF) is a clinically approved traditional Chinese medicine used for treating respiratory infectious diseases. However, its effects and mechanism in the context of ALI remain poorly understood. In this study, we investigated the potential of JF to alleviate ALI by reducing inflammation and necroptosis of lung epithelial cells. Methods: The effects of JF on ALI were evaluated using an integrative pharmacological strategy. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to identify the bioactive compounds of JF present in the serum of ALI mice, which are responsible for its therapeutic efficacy in treating ALI. ALI mouse models were established by the nasal drops of Poly (I∶C) over 3 days, followed by, intragastric administration of JF four times. We investigated Changes in lung function, inflammatory cytokines, pathological morphology of lung tissue, mitochondrial indicators, both transcriptomic and metabolomic profiles of the lung tissue, and necroptosis of lung epithelial cells. Results: JF reduced airway resistance in ALI mice ( Conclusion: JF can ameliorate ALI through various mechanisms, including its anti-inflammatory activity, inhibition of necroptosis, and enhancement of mitochondrial bioenergetics to promote ATP biosynthesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.